Moreover, the expression of DAPK1 correlated with several targeting drugs (DB04069: 5,6-Dihydro-Benzo [H]Cinnolin-3-Ylamine, DB04395: Phosphoaminophosphonic Acid-Adenylate Ester, DB07444: 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO [3,4-C]CARBAZOLE-1,3(2H, 6H)-DIONE), as shown in Figure 4D, which implied considerable promise for immunotherapy in HCC. The gene discussed is DAPK1; the disease is hepatocellular carcinoma.